Neuroimmune pathways as targets for precision treatment in alcohol use disorder: A commentary on biomarkers for craving
Abstract
CLH-K holds two patents for the development of negative allosteric modulators targeting the stress system and one patent application on the development of a compound for noradrenergic blockade. All is unrelated to this work. CLH-K serves as Site PI on Eli Lilly and Altimmune-sponsored clinical trials. LNS reports no conflicts of interest.
Fields of Study & Subjects
Tryptophan and brain disorders
Neuroinflammation and Neurodegeneration Mechanisms
Neurotransmitter Receptor Influence on Behavior
Publication details
- Journal / source
- Alcoholism Clinical and Experimental Research
- Publisher
- Wiley
- Volume
- 50
- Issue
- 1
- Pages
- e70229–e70229
- Publication date
- 1 January 2026
- Language
- EN